ReviewFEBS letters2014
Cardiac to cancer: connecting connexins to clinical opportunity.
Review in FEBS letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and Clinic Pathological Value of Cx43 Expression in Glioma: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.The Journal of investigative dermatology · 2015Trial
- Safety, tolerability and preliminary efficacy of ALMB-0166 in patients with acute spine cord injury.Brain communications · 2026Article
- Reduced gap junction coupling amplifies the effects of cardiomyocyte variability and destabilizes the heartbeat.Physiological reports · 2025Article
- Article
- Article
- Correlation between connexin 43 expression in circulating tumor cells and biological characteristics of breast cancer.Heliyon · 2023Article
- Peptidic Connexin43 Therapeutics in Cardiac Reparative Medicine.Journal of cardiovascular development and disease · 2021Review
- Effects of Alpha-Connexin Carboxyl-Terminal Peptide (aCT1) and Bowman-Birk Protease Inhibitor (BBI) on Canine Oral Mucosal Melanoma (OMM) Cells.Frontiers in veterinary science · 2021Article
- The Role of Connexin-43 in the Inflammatory Process: A New Potential Therapy to Influence Keratitis.Journal of ophthalmology · 2019Review
- Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.Current opinion in pharmacology · 2018Review
- Connexin 43-Based Therapeutics for Dermal Wound Healing.International journal of molecular sciences · 2018Review
- Connexins: Synthesis, Post-Translational Modifications, and Trafficking in Health and Disease.International journal of molecular sciences · 2018Review
- The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response.International journal of molecular sciences · 2018Review
- Joint diseases: from connexins to gap junctions.Nature reviews. Rheumatology · 2017Review
- Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration.Oncotarget · 2017Article
- Mechanism of action of the anti-inflammatory connexin43 mimetic peptide JM2.American journal of physiology. Cell physiology · 2017Article
- Gap junctional signaling in pattern regulation: Physiological network connectivity instructs growth and form.Developmental neurobiology · 2017Review
- The role of gap junctions in inflammatory and neoplastic disorders (Review).International journal of molecular medicine · 2017Review
- Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gap junctions and their connexin components are indispensable in mediating the cellular coordination required for tissue and organ homeostasis. The critical nature of their existence mandates a connection to disease while at the same time offering therapeutic potential. Therapeutic intervention may be offered through the pharmacological and molecular disruption of the pathways involved in connexin biosynthesis, gap junction assembly, stabilization, or degradation. Chemical inhibitors aimed at closing connexin channels, peptide mimetics corresponding to short connexin sequences, and gene therapy approaches have been incredibly useful molecular tools in deciphering the complexities associated with connexin biology. Recently, therapeutic potential in targeting connexins has evolved from basic research in cell-based models to clinical opportunity in the form of human trials. Clinical promise is particularly evident with regards to targeting connexin43 in the context of wound healing. The following review is aimed at highlighting novel advances where the pharmacological manipulation of connexin biology has proven beneficial in animals or humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.